Drug Trial Radar · NCT07187713
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 20, 2025
Primary completion
Aug 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Ace Cells Lab LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria/proteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux/UTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-transplant proteinuria. Nephropathy remains a global health burden, with \~9-10% of the population affected by chronic kidney disease (CKD), equating to \>750 million individuals worldwide. The socioeconomic costs are substantial: in England CKD costs \~£7 billion annually, projected to rise to \~£14 billion by 2033; in Malaysia, prevalence rose from 9% to 15.5% within 7 years; in Egypt, CKD imposes heavy familial and financial burdens, especially for pediatric patients; in Turkey, CKD is among the top causes of disability, linked to the rising tide of diabetes, obesity, and hypertension. ACE Reno is designed to address multiple drivers of CKD progression - glomerulosclerosis, fibrosis, endothelial dysfunction, and maladaptive RAAS/aldosterone signaling - through its peptide components that mimic antifibrotic (BMP-7, HGF, Klotho-like) and vasodilatory/cGMP-mediated (natriuretic peptide-like) pathways.
Conditions
- Hypertensive Nephropathy
- Auto Immune Disorders
- Chronic Kidney Disease
- Chronc Kidney Disease Stage 5
- Chronic Kidney Disease (Stage 3-4)
- Chronic Kidney Disease (Stages 4 and 5)
- Microalbuminuria
- Diabetic Nephropathies
Interventions
ACE RenoDrug
1 ml sublingual 4 times daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Urinary Albumin-to-Creatinine Ratio (ACR)Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
British Centre For Regenerative medicine BCRMED Global
Giza, GZ, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.